Connect Biopharma (CNTB) Competitors

$2.38 0.00 (0.00%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$2.43 +0.05 (+2.06%)

As of 06:42 AM Eastern

CNTB vs. ANL, IMMX, FDMT, STTK, and OCGN

Should you buy Connect Biopharma stock or one of its competitors? MarketBeat compares Connect Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Connect Biopharma include Adlai Nortye (ANL), Immix Biopharma (IMMX), 4D Molecular Therapeutics (FDMT), Shattuck Labs (STTK), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry.

How does Connect Biopharma compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Connect Biopharma had 12 more articles in the media than Adlai Nortye. MarketBeat recorded 16 mentions for Connect Biopharma and 4 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.58 beat Connect Biopharma's score of -0.42 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adlai Nortye currently has a consensus price target of $21.67, indicating a potential upside of 60.38%. Connect Biopharma has a consensus price target of $8.67, indicating a potential upside of 264.15%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Adlai Nortye has higher revenue and earnings than Connect Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	108.08	-$35.53M	N/A	N/A
Connect Biopharma	$60K	2,497.41	-$55.48M	-$1.15	N/A

Adlai Nortye has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market.

Adlai Nortye's return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Connect Biopharma	N/A	-122.29%	-97.07%

Summary

Connect Biopharma beats Adlai Nortye on 7 of the 13 factors compared between the two stocks.

How does Connect Biopharma compare to Immix Biopharma?

Connect Biopharma (NASDAQ:CNTB) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Connect Biopharma presently has a consensus price target of $8.67, suggesting a potential upside of 264.15%. Immix Biopharma has a consensus price target of $18.25, suggesting a potential upside of 83.60%. Given Connect Biopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Connect Biopharma is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Immix Biopharma's return on equity of -73.24% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
Immix Biopharma	N/A	-73.24%	-59.20%

Connect Biopharma has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market.

Immix Biopharma has lower revenue, but higher earnings than Connect Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,497.41	-$55.48M	-$1.15	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

In the previous week, Connect Biopharma had 15 more articles in the media than Immix Biopharma. MarketBeat recorded 16 mentions for Connect Biopharma and 1 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.89 beat Connect Biopharma's score of -0.42 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Connect Biopharma	Neutral
Immix Biopharma	Very Positive

Summary

Immix Biopharma beats Connect Biopharma on 8 of the 15 factors compared between the two stocks.

How does Connect Biopharma compare to 4D Molecular Therapeutics?

Connect Biopharma (NASDAQ:CNTB) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Connect Biopharma has higher earnings, but lower revenue than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,497.41	-$55.48M	-$1.15	N/A
4D Molecular Therapeutics	$88.24M	5.42	-$140.11M	-$2.57	N/A

In the previous week, Connect Biopharma had 2 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 16 mentions for Connect Biopharma and 14 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.78 beat Connect Biopharma's score of -0.42 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
4D Molecular Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Connect Biopharma presently has a consensus price target of $8.67, suggesting a potential upside of 264.15%. 4D Molecular Therapeutics has a consensus price target of $29.88, suggesting a potential upside of 226.50%. Given Connect Biopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Connect Biopharma is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Connect Biopharma has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Connect Biopharma has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.77, suggesting that its share price is 177% more volatile than the broader market.

Summary

Connect Biopharma beats 4D Molecular Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Connect Biopharma compare to Shattuck Labs?

Connect Biopharma (NASDAQ:CNTB) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by company insiders. Comparatively, 8.8% of Shattuck Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Shattuck Labs has higher revenue and earnings than Connect Biopharma. Shattuck Labs is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,497.41	-$55.48M	-$1.15	N/A
Shattuck Labs	$1M	480.02	-$48.81M	-$0.63	N/A

In the previous week, Connect Biopharma had 11 more articles in the media than Shattuck Labs. MarketBeat recorded 16 mentions for Connect Biopharma and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.00 beat Connect Biopharma's score of -0.42 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Shattuck Labs	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Connect Biopharma has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Connect Biopharma presently has a consensus target price of $8.67, suggesting a potential upside of 264.15%. Shattuck Labs has a consensus target price of $13.00, suggesting a potential upside of 107.67%. Given Connect Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Connect Biopharma is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Shattuck Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Shattuck Labs' return on equity of -60.73% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
Shattuck Labs	N/A	-60.73%	-55.75%

Summary

Shattuck Labs beats Connect Biopharma on 9 of the 16 factors compared between the two stocks.

How does Connect Biopharma compare to Ocugen?

Connect Biopharma (NASDAQ:CNTB) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Comparatively, 4.0% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Connect Biopharma has higher earnings, but lower revenue than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,497.41	-$55.48M	-$1.15	N/A
Ocugen	$4.41M	106.70	-$67.85M	-$0.24	N/A

In the previous week, Ocugen had 10 more articles in the media than Connect Biopharma. MarketBeat recorded 26 mentions for Ocugen and 16 mentions for Connect Biopharma. Ocugen's average media sentiment score of 0.37 beat Connect Biopharma's score of -0.42 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocugen	5 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Connect Biopharma has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.3, suggesting that its share price is 130% more volatile than the broader market.

Connect Biopharma currently has a consensus target price of $8.67, suggesting a potential upside of 264.15%. Ocugen has a consensus target price of $9.75, suggesting a potential upside of 601.44%. Given Ocugen's higher probable upside, analysts clearly believe Ocugen is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Connect Biopharma has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Connect Biopharma's return on equity of -122.29% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
Ocugen	-1,192.18%	-127,987.80%	-135.48%

Summary

Connect Biopharma beats Ocugen on 10 of the 17 factors compared between the two stocks.

Get Connect Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTB vs. The Competition

Export

Metric	Connect Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$149.85M	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.81%	5.30%
P/E Ratio	-2.07	18.50	20.40	25.26
Price / Sales	2,497.41	287.14	550.85	73.54
Price / Cash	N/A	55.27	27.48	37.27
Price / Book	3.17	6.76	9.74	6.71
Net Income	-$55.48M	$24.40M	$3.57B	$336.00M
7 Day Performance	1.71%	-1.08%	-1.05%	-0.72%
1 Month Performance	-15.30%	-4.84%	-2.62%	-0.09%
1 Year Performance	216.91%	62.87%	33.52%	30.62%

Connect Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTB Connect Biopharma	2.9153 of 5 stars	$2.38 flat	$8.67 +264.1%	+216.9%	$149.85M	$60K	N/A	110	Trending News Earnings Report Upcoming Earnings Analyst Downgrade
ANL Adlai Nortye	2.1176 of 5 stars	$12.96 -2.4%	$21.50 +65.9%	+578.9%	$531.20M	$5M	N/A	127	Gap Up
IMMX Immix Biopharma	2.7816 of 5 stars	$9.92 +1.7%	$18.25 +84.0%	+382.5%	$530.51M	N/A	N/A	9	Positive News
FDMT 4D Molecular Therapeutics	2.7955 of 5 stars	$10.79 +6.4%	$29.88 +176.9%	+166.0%	$530.07M	$88.24M	N/A	120	Gap Up
STTK Shattuck Labs	3.0115 of 5 stars	$7.02 +2.5%	$13.00 +85.2%	+469.1%	$525.26M	$1M	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTB) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Connect Biopharma (CNTB) Competitors

CNTB vs. ANL, IMMX, FDMT, STTK, and OCGN

How does Connect Biopharma compare to Adlai Nortye?

Summary

How does Connect Biopharma compare to Immix Biopharma?

Summary

How does Connect Biopharma compare to 4D Molecular Therapeutics?

Summary

How does Connect Biopharma compare to Shattuck Labs?

Summary

How does Connect Biopharma compare to Ocugen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Connect Biopharma (CNTB) Competitors

CNTB vs. ANL, IMMX, FDMT, STTK, and OCGN

How does Connect Biopharma compare to Adlai Nortye?

Do insiders and institutionals have more ownership in ANL or CNTB?

Does the media prefer ANL or CNTB?

Do analysts recommend ANL or CNTB?

Which has better valuation and earnings, ANL or CNTB?

Which has more risk & volatility, ANL or CNTB?

Is ANL or CNTB more profitable?

Summary

How does Connect Biopharma compare to Immix Biopharma?

Do analysts rate CNTB or IMMX?

Do institutionals and insiders have more ownership in CNTB or IMMX?

Is CNTB or IMMX more profitable?

Which has more volatility & risk, CNTB or IMMX?

Which has stronger valuation and earnings, CNTB or IMMX?

Does the media favor CNTB or IMMX?

Summary

How does Connect Biopharma compare to 4D Molecular Therapeutics?

Which has stronger valuation and earnings, CNTB or FDMT?

Does the media favor CNTB or FDMT?

Do analysts rate CNTB or FDMT?

Is CNTB or FDMT more profitable?

Do institutionals and insiders have more ownership in CNTB or FDMT?

Which has more volatility & risk, CNTB or FDMT?

Summary

How does Connect Biopharma compare to Shattuck Labs?

Do insiders & institutionals have more ownership in CNTB or STTK?

Which has preferable earnings and valuation, CNTB or STTK?

Does the media favor CNTB or STTK?

Which has more volatility and risk, CNTB or STTK?

Do analysts rate CNTB or STTK?

Is CNTB or STTK more profitable?

Summary

How does Connect Biopharma compare to Ocugen?

Do institutionals & insiders have more ownership in CNTB or OCGN?

Which has better earnings & valuation, CNTB or OCGN?

Does the media refer more to CNTB or OCGN?

Which has more risk and volatility, CNTB or OCGN?

Do analysts rate CNTB or OCGN?

Is CNTB or OCGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools